Oregon’s pioneering psilocybin therapy program is drawing a familiar mix of optimism and concern as new reviews highlight who is using it and how. High-income clients, many traveling from out of state, continue to dominate access to supervised mushroom sessions, often for wellness or “personal growth” rather than diagnosed mental illness. Researchers warn that limited reporting requirements make it hard to know whether service centers are consistently screening out people for whom psychedelics could be risky.
Yet evidence from initiatives such as Oregon Health & Science University’s long-term study suggests supervised psilocybin has real potential to help with mental health and substance use when delivered safely. As the Bend Source editorial argues, the challenge now is less about predicting problems and more about fixing them—by tightening safeguards, expanding access, and grounding debate in data. You can read the original commentary, “Much Ado About Psilocybin,” at The Source Weekly.